Effect of Low and High Dose Sugammadex on Erythrocyte Deformability in Streptozotocin-Induced Diabetic Rats

dc.authoridArslan, Mustafa/0000-0003-4882-5063
dc.authoridAYDIN, Muhammed Enes/0000-0001-8491-6566
dc.contributor.authorKiraz, Hasan Ali
dc.contributor.authorTurgut, Huseyin Cihad
dc.contributor.authorKartal, Seyfi
dc.contributor.authorComu, Faruk Metin
dc.contributor.authorKip, Glay
dc.contributor.authorAlkan, Metin
dc.contributor.authorAydin, Muhammed Enes
dc.date.accessioned2025-01-27T21:19:21Z
dc.date.available2025-01-27T21:19:21Z
dc.date.issued2015
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective: Erythrocyte deformability is a function of specially designed erythrocyte membrane properties and allows for the oxygen delivery without cell fragmentation. Impaired erythrocyte deformability in diabetes is one of the suspected factors that result in erythrocyte aggregation and the microvascular circulatory arrest. In this study, we aimed to investigate low versus high doses of sugammadex on erythrocyte deformability in streptozototocin-induced diabetic rats. Methods: Twenty-four male Wistar albino rats weighing between 225 and 300 gr were randomly divided into 4 groups. Group C (control; n=6), Group DC (diabetes control; n=6), Group DR-16S (diabetes-rocuronium-16mg sugammadex; n=6) and Group DR-96S (diabetes- rocuronium-96mg sugammadex; n=6). Rats in control and diabetes groups received a 0.9% NaCl solution at the same volume. Diabetes was induced by a single IP injection of streptozotocin (Sigma Chemical, St. Louis, MO, USA) at a dose of 55 mg.kg(-1) body weight, and animals were kept alive for 30 days. At the end of the follow-up period animals erythrocyte deformability was measured from blood samples. Results: Serum glucose was significantly lower in Group C as compared to Groups DC, DR-16S and DR-96S (p<0.0001). The deformability index was significantly increased in the diabetic rats (p<0.0001). It was significantly increased in Group DR-96S as compared to Group C and DC (p<0.0001, p=0.028, respectively). Conclusion: In this study, we showed the safety profile of low dose sugammadex in diabetic rats in terms of the erythrocyte deformability. Our findings may lead to future animal and human studies investigating sugammadex effects on erythrocyte deformability and micro/macrovascular circulation.
dc.identifier.doi10.12996/gmj.2015.32
dc.identifier.endpage109
dc.identifier.issn2147-2092
dc.identifier.issue3
dc.identifier.scopus2-s2.0-84936873231
dc.identifier.scopusqualityQ4
dc.identifier.startpage107
dc.identifier.urihttps://doi.org/10.12996/gmj.2015.32
dc.identifier.urihttps://hdl.handle.net/20.500.12428/28564
dc.identifier.volume26
dc.identifier.wosWOS:000217477300008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherGazi Univ, Fac Med
dc.relation.ispartofGazi Medical Journal
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectErythrocyte deformability
dc.subjectdiabetes
dc.subjectsugammadex
dc.subjectmicrocirculation
dc.titleEffect of Low and High Dose Sugammadex on Erythrocyte Deformability in Streptozotocin-Induced Diabetic Rats
dc.typeArticle

Dosyalar